Varon D, Martinowitz U
National Haemophilia Center, Sheba Medical Center, Tel Hashomer, Israel.
Haemophilia. 1998 Jul;4(4):431-5. doi: 10.1046/j.1365-2516.1998.440431.x.
The application of coagulation factor therapy by continuous infusion (CI) was first suggested by Brinkhous in the early 1950s. The recent introduction of this mode of therapy to everyday practice was made possible after the demonstration of a good stability of most factor concentrates which were also found safe regarding potential bacterial contamination. Other developments included a better understanding of the pharmacokinetics of factors concentrates as well as the availability of a new delivery system. Continuous infusion was shown to be superior to bolus injection (BI) in achieving a stabile haemostatic effect, in the prevention of post-operative bleeding and was found to save between 20-50% in the required factor. This mode of therapy was found effective in haemophilia A and B as well as among patients with inhibitors to FVIII and with von Willebrand disease (vWD).
20世纪50年代初，布林克豪斯首次提出持续输注（CI）凝血因子疗法。在证实大多数凝血因子浓缩剂具有良好的稳定性且在潜在细菌污染方面也被认为是安全的之后，这种治疗方式最近才得以应用于日常实践。其他进展包括对凝血因子浓缩剂药代动力学有了更好的理解以及出现了新的给药系统。在实现稳定的止血效果、预防术后出血方面，持续输注被证明优于大剂量注射（BI），并且发现所需凝血因子可节省20%-50%。这种治疗方式在A型和B型血友病患者以及FVIII抑制剂患者和血管性血友病（vWD）患者中均被证明有效。
